Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.
The polyclonal cytokine-induced killer (CIK) cells exhibit potent cytotoxicity against a variety of tumour cells including autologous and allogeneic acute myeloid leukaemic (AML) targets. At maturity, three lymphocyte subsets: CD3(-) CD56(+), CD3(+) CD56(-) and CD3(+) CD56(+), constitute the bulk of the CIK cell culture. The CD3(-) CD56(+) subset behaves like classical natural killer (NK) cells where cytotoxicity is potentiated by blocking the human leucocyte antigen Class I molecules in the AML targets. Both the CD3(+) CD56(+) and CD3(+) CD56(-) subsets, though known to kill autologous and allogeneic targets to a comparable degree and therefore non-major histocompatibility complex (MHC)-restricted, nevertheless require the presence of the MHC molecule on the target, which interacts with their CD3-T-cell receptor complex. Although CIK cells are often termed 'NK-like' T cells, we have demonstrated that the well-characterized NK receptors KIR, NKG2C/E, NKG2D and DNAM-1 are not involved in the process of AML recognition for the CD3(+) CD56(-) and CD3(+) CD56(+) subsets. The CD3(+) CD56(+) and CD3(+) CD56(-) subsets express a polyclonal and comparable TCRVbeta repertoire in a Gaussian distribution. The CD3(+) CD56(+) subset kills AML targets more efficiently than its CD3(+) CD56(-) counterpart because of the presence of a higher proportion of CD8(+) cells. The CD3(+) CD56(+) subset comprise more terminally differentiated late effector T cells that bear the CD27(+) CD28(-) or CD27(-) CD28(-) phenotype, with a higher granzyme A content. In comparison, the phenotype of the CD3(+) CD56(-) subset is consistent with early effector T cells that are CD27(+) CD28(+) and CD62L(+), known to be less cytotoxic but possess greater proliferative potential.
Linn
Yeh C
YC
Department of Haematology, Singapore General Hospital, Singapore.
Lau
Siew Kee J
SK
Liu
Bee H
BH
Ng
Lee H
LH
Yong
Hao X
HX
Hui
Kam M
KM
D017252:CD3 Complex / Q000032:analysis; D019002:CD56 Antigen / Q000032:analysis; D055612:Cytokine-Induced Killer Cells / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000473:pathology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000378:metabolism; D011971:Receptors, Immunologic / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D014407:Tumor Cells, Cultured
D017252:CD3 Complex; D019002:CD56 Antigen; D016693:Receptors, Antigen, T-Cell, alpha-beta; D011971:Receptors, Immunologic
J Clin Invest. 2005 Jun;115(6):1616-26
15931392
Cancer Res. 2004 Feb 1;64(3):1171-80
14871854
Clin Cancer Res. 2006 Mar 15;12(6):1859-67
16551871
Haematologica. 2001 Oct;86(10):1029-37
11602408
Br J Haematol. 2002 Jan;116(1):78-86
11841399
J Clin Invest. 2002 Jul;110(2):185-92
12122110
Cancer Res. 2001 Sep 15;61(18):6846-50
11559560
J Immunol. 1994 Aug 15;153(4):1687-96
7519209
J Exp Med. 1991 Jul 1;174(1):139-49
1711560
Blood. 2003 Jan 15;101(2):640-8
12393519
J Clin Oncol. 2005 Apr 1;23(10):2346-57
15800326
Br J Cancer. 1999 Nov;81(6):1009-16
10576658
Blood. 2005 Jun 15;105(12):4583-9
15746083
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7159-63
2674949
J Immunol. 1998 Apr 1;160(7):3111-20
9531265
J Immunol. 2002 May 15;168(10):4864-70
11994435
Cancer Res. 2002 Nov 1;62(21):6178-86
12414645
Blood. 2001 May 15;97(10):2923-31
11342413
Exp Hematol. 2005 Jun;33(6):671-81
15911091
Blood. 2004 Apr 15;103(8):3065-72
15070686
Biol Blood Marrow Transplant. 2001;7(4):216-22
11349808
Mol Ther. 2001 Jan;3(1):54-60
11162311
Biol Blood Marrow Transplant. 2002;8(10):557-68
12434951
Blood. 2004 May 15;103(10):3982-5
14764538
Immunity. 1996 Jun;4(6):573-81
8673704
J Clin Invest. 2005 Jun;115(6):1467-9
15931384
Exp Hematol. 1993 Dec;21(13):1673-9
7694868
Blood. 1998 Nov 1;92(9):3318-27
9787169
Blood. 2005 Jan 1;105(1):241-50
15345595
Cell Immunol. 1996 Apr 10;169(1):85-90
8612299
Blood. 2005 Mar 1;105(5):2066-73
15536144
J Immunol. 1994 May 15;152(10):5109-19
8176227
Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7
15744236
Zhonghua Nei Ke Za Zhi. 2005 Mar;44(3):198-201
15840260